Novo Nordisk's obesity drug Wegovy debuts in Thailand
BANGKOK, April 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's local subsidiary said on Monday, marking the injectable drug's first entry into the Southeast Asian market.
First launched in 2021, Wegovy helped make Novo Nordisk Europe's most valuable listed company until recently, worth $615 billion at its peak.
here.
Wegovy is available in more than a dozen countries including the United States, Japan and China, with Thailand becoming its latest market.
"We actually received the Thai FDA approval already in 2023," said Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary. He noted that Novo was making Wegovy available in Thailand ahead of rival Eli Lilly 's (LLY.N), opens new tab Zepbound weight loss drug.
Bruland declined to provide details on Wegovy's pricing in Thailand, which has a population of around 66 million, or Novo Nordisk's plans for expansion into other Southeast Asian markets.
Wegovy is currently available for prescription in private hospitals around the country and will be available soon in public hospitals, Bruland said.
"Over the last four years, we have invested approximately 500 million Thai baht in clinical trials in Thailand," he said.
Novo Nordisk's diabetes drug Ozempic, which contains the same active ingredient as Wegovy, is already available in Thailand.
About 42% of Thailand's adult population is considered obese, and the rate of obesity in school children surged from 5.8% to 15% within two decades, according to data from the country's health ministry.
"If we then look at the economic impact that this has, approximately 1 percent of GDP is used for health-related costs that come with obesity and productivity loss," Bruland said.
"We believe with this innovation, we can make a big difference and hopefully bend this curve."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wales Online
8 hours ago
- Wales Online
Welsh tourist vanishes on holiday and found on life support in hospital
Welsh tourist vanishes on holiday and found on life support in hospital It's thought 29-year-old Ashton Jones, from Cwmbran, was violently attacked after he became separated from his friends Ashton Jones is gravely ill in a Thai hospital (Image: Wales News Service ) A British tourist who mysteriously vanished on a night out in Thailand was found on life support in hospital – and his family fear he won't survive unless he is brought back home. Ashton Jones, 29, went on a last-minute trip to Bangkok but was separated from his friends on a night out. His family have no idea what happened before he was found in a hospital having emergency brain surgery – and is now fighting for his life nearly 6,000 miles away from home. And to make it worse Ashton didn't take out holiday insurance before jetting off 6,000 miles to Bangkok. Read the biggest stories in Wales first by signing up to our daily newsletter here. His worried grandmother Beverley Walker, of Cwmbran is desperately trying to raise money to pay for his medical care and bring him back home to Wales. She said Ashton had travelled to Thailand with a lifelong friend on May 30 and on arrival met up with another friend. Article continues below Ashton Jones with his grandmother Beverley Walker (Image: Wales News Service ) But five days into his trip the family received the worst news that he had gone missing after a night out partying. His friends spent hours searching for Ashton after he went missing from the nightclub they were in. He was found in hospital in Thailand and medics believe Ashton, who has epilepsy, was violently attacked. Beverley said: 'I am deeply concerned that without immediate financial or diplomatic assistance my grandson may not survive. 'The emotional toll on our family is immense. We are heartbroken and fearful, watching from afar while Ashton suffers without the care he urgently requires.' Beverley said on Monday, nearly a week after Ashton went into hospital on June 3, workers at Chonburi Hospital tried to wake him up. She added: 'It was a success but he still has a long way to go. He's bedbound and suffering with fits, cannot talk, eat, or drink and isn't aware. 'We all as a family are worried sick with fear for Ashton and how we can bring him home.' Ashton's trip was only booked at the last minute and he didn't have any travel insurance (Image: Wales News Service ) But Ashton's treatment and funding to bring him to the UK will cost the family thousands, which is way more than they can afford to pay. As he went out to Thailand at short notice Beverley said he 'did the unthinkable' and travelled without taking out any insurance. The family have set up a GoFundMe page in a bid to raise £50,000 to help cover medical expenses and to bring him home. So far more than £3,000 has been raised by more than 100 donors since the fundraiser was launched. Beverley said: 'The hospital in Thailand is asking for the cost of his treatment on going that is far beyond what our family can afford. 'In the meantime Ashton's condition continues to deteriorate and it feels as though we are being left helpless as time runs out. 'We have already put together life savings for medical bills, flights, travel, accommodation to be with him but would never be able to afford to get him home to better health care and his family. 'We all as a family are worried sick with fear for Ashton and how we can bring him home. 'So please any donations made towards getting Ashton home is appreciated beyond words can describe. 'From the bottom of our hearts thank you.' You can donate to the fundraiser here. Article continues below A Foreign Office spokesman said: 'We are supporting a British man who has been hospitalised in Thailand and are in contact with the local authorities.' Get daily breaking news updates on your phone by joining our WhatsApp community here. We occasionally treat members to special offers, promotions and ads from us and our partners. See our Privacy Notice.
Medical News Today
8 hours ago
- Medical News Today
Contrave vs. Wegovy: What to know about each
Contrave (naltrexone/bupropion) and Wegovy (semaglutide) are brand-name drugs. They're both prescribed for weight loss in adults. This article explains the main similarities and differences between Contrave and Wegovy. If you're considering taking one of these drugs, discussing this information with your doctor can help you decide whether one of these treatments may be right for you. Note: For more comprehensive information about these two drugs, you can refer to our Contrave and Wegovy articles. These are a few of the main differences between Contrave and Wegovy: Form: Contrave comes as an extended-release oral tablet, while Wegovy is a solution in prefilled, single-use pens that administer the medication as a subcutaneous injection. ('Extended-release' means the drug slowly releases into your body over a long period of time.) Contrave comes as an extended-release oral tablet, while Wegovy is a solution in prefilled, single-use pens that administer the medication as a subcutaneous injection. ('Extended-release' means the drug slowly releases into your body over a long period of time.) Dosage : Contrave is taken more often than Wegovy. (See the Dosage section.) : Contrave is taken more often than Wegovy. (See the Dosage section.) Conditions treated: Contrave and Wegovy are both used for weight loss in certain adults, but Wegovy is also used for weight management in certain children and to lower certain cardiovascular risks in certain adults. (See the Uses section.) Contrave and Wegovy have been approved by the Food and Drug Administration (FDA) for the following uses in adults, in combination with exercise and a reduced-calorie diet. Contrave and Wegovy are FDA approved for: Wegovy is also FDA approved to: lower the risk of serious cardiovascular (heart and blood vessel) events, including non-fatal heart attack or stroke, in adults with cardiovascular disease, or who have obesity or are considered overweight Wegovy is approved for weight loss and management in children ages 12 years and older with obesity, usually defined as a BMI of 30 kg/m2 or greater. Contrave is not approved for use in children. The medication has a boxed warning that includes a note that it has not been studied in children. To learn more about this warning, see 'Precautions for Contrave and Wegovy'. Note: For more information about the drugs' uses, see our articles about Contrave and Wegovy. Here's a quick look at the dosage and administration of Contrave and Wegovy for the conditions they treat. Below is information on Contrave and Wegovy dosages for weight management in adults. Wegovy comes as a solution inside prefilled, single-use pens given as a subcutaneous injection. When you're first prescribed Wegovy, a healthcare professional will show you how to give yourself the injections. You can also refer to the 'How to Take Wegovy' guide from the manufacturer. Note: For more information about dosage, see our dosage articles about Contrave and Wegovy. Contrave and Wegovy are both used for weight management in certain adults. These drugs can cause some of the same side effects, as well as different ones. Some of the side effects reported in clinical trials of these drugs are listed here. The following table lists some of the more commonly reported mild side effects of Contrave and Wegovy. The table may also include mild side effects that are less common, but you may have concerns about them in some cases. These side effects may be temporary, lasting a few days to weeks. If the side effects last longer than that, bother you, or become severe, be sure to talk with your doctor or pharmacist. The following table lists reported serious side effects of Contrave and Wegovy. If you have serious side effects while using Contrave or Wegovy, call your doctor immediately. If the side effects feel life threatening or you believe you're having a medical emergency, call 911 or your local emergency number right away. * Contrave has a boxed warning for this side effect. A boxed warning is a serious warning from the FDA. To learn more, see the 'Precautions for Contrave and Wegovy' section. ** Wegovy has a boxed warning for this side effect. A boxed warning is a serious warning from the FDA. To learn more, see the 'Precautions for Contrave and Wegovy' section. ALLERGIC REACTION For some people, Contrave and Wegovy can cause an allergic reaction. In general, symptoms of an allergic reaction can be mild or serious. Ways to manage For mild allergic reaction symptoms, such as a mild rash, call your doctor right away. They may recommend treatments to help manage your symptoms. They'll also let you know whether you should keep taking the medication. For severe allergic reaction symptoms, such as swelling or trouble breathing, call 911 or your local emergency number right away. These symptoms require immediate medical care because they can become life threatening. If you've had a serious allergic reaction to Contrave, your doctor may recommend taking a different medication instead. Here are answers to some common questions about Contrave and Wegovy. It's not clear. Currently, there aren't enough studies evaluating whether it's safe to take Contrave and Wegovy for weight loss together or if taking them together is more effective for weight loss and management than taking either medication on their own. In fact, the prescribing information for Contrave specifically notes that it hasn't been studied in combination with other medications for weight loss. Due to the lack of evidence, your doctor may not prescribe Contrave and Wegovy together. Contrave and Wegovy can cause some similar side effects, including increased heart rate. Taking them together may further raise your risk for certain side effects caused by both medications. Talk with your doctor if you're thinking about taking Wegovy or Contrave for weight loss. They can help determine the best treatment plan for you. You may wonder how Wegovy and Contrave compare to Ozempic, Qsymia, Saxenda, and similar medications. The table below includes a few key details on how Contrave and Wegovy compare to similar drugs. It's important to note that some of these drugs are approved for different uses. Your doctor can help determine which of these medications is the best fit for you based on your treatment needs. Contrave and Wegovy are both FDA approved for: weight loss and management, in adults with a BMI of 30 kg/m 2 or greater, which indicates obesity or greater, which indicates obesity weight loss and management, in adults with a BMI of 27 kg/m2 or greater (which is considered overweight) who also have at least one weight-related condition, including high blood pressure, high cholesterol, or type 2 diabetes If you're considering treatment with either medication for these uses, you may wonder how their effectiveness compares. Prescribing information: Both Contrave and Wegovy were found to be effective for weight loss and management in certain adults in clinical trials. For details about how these drugs performed in clinical trials, see the prescribing information for Contrave and Wegovy. Keep in mind that trial results may not apply to your individual health situation. Treatment guidelines: Another way to determine whether a drug is considered effective is to look at treatment guidelines. When an organization includes certain drugs in treatment guidelines, this means research has shown the drug to be safe and effective. Both Contrave and Wegovy are recommended as a treatment option for weight loss and management in certain adults in guidelines from the American Gastroenterological Association. How much Contrave or Wegovy costs depends on the treatment plan your doctor prescribes, your insurance plan, and your pharmacy. You can visit Optum Perks for price estimates of Contrave and Wegovy. (Optum Perks is a sister site of Medical News Today.) Both Contrave and Wegovy are brand-name drugs. Neither Contrave nor Wegovy is available in a generic form. Brand-name medications often cost more than generics. Talk with your doctor or pharmacist to learn about the generic form of either drug. Contrave and Wegovy may not be right for you if you have certain medical conditions or other factors that affect your health. These drugs have some of the same precautions, but they also have different ones. Some of these precautions are mentioned here. Wegovy has a boxed warning for the risk of thyroid cancer. A boxed warning is a serious warning from the Food and Drug Administration (FDA). A boxed warning alerts doctors and patients about drug effects that may be dangerous. During treatment with Wegovy, let your doctor know if you have symptoms of thyroid tumors or cancer. Examples include a hoarse voice that doesn't go away, a mass or lump in your neck, and shortness of breath. Contrave has a boxed warning about the risk for suicidal thoughts and behaviors. Risk for suicidal thoughts and behaviors: Contrave contains bupropion as one of its active ingredients (what makes a drug work). Bupropion is an antidepressant, and antidepressants may cause a small increase in risk for suicidal thoughts and behaviors. This risk applies to children and adults ages 24 and under, based on a large review of studies evaluating short-term antidepressant use. It's important to note that Contrave is not approved for use in children. Contrave is also not approved for treating depression or any other mental health condition. In addition to boxed warnings, Contrave and Wegovy have other warnings. If any of the following medical conditions or other health factors are relevant to you, talk with your doctor before using Contrave or Wegovy. Note: For more comprehensive information about these drugs, you can refer to our Contrave and Wegovy articles. Switching between Contrave and Wegovy might be possible. Both Contrave and Wegovy are approved for weight loss and management, along with diet and exercise, in certain adults. If you're taking Wegovy to lower your risk for certain cardiovascular problems, your doctor likely will not switch you to Contrave for this use. This isn't an approved use for Contrave. If you'd like to know more about switching between Contrave and Wegovy, talk with your doctor. They can give you additional details and help determine the best course of action for your personal situation. Even if two drugs treat the same condition or are in the same drug class, your body can still respond differently. It's important that you do not stop, start, or switch any of your drug treatments without your doctor's recommendation. Disclaimer: Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses. Medical News Today has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources to ensure content accuracy and integrity. You can learn more about how we ensure our content is accurate and current by reading our editorial policy.
Reuters
9 hours ago
- Reuters
Health Rounds: Patients drop fewer pounds with weight-loss drugs in real world than in trials
June 11 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) People who take weight-loss drugs hoping to achieve the impressive results observed in large clinical trials may need to adjust their expectations, a new study suggests. In a real-world study of nearly 8,000 patients taking Novo Nordisk's ( opens new tab Wegovy or Ozempic, or Eli Lilly's (LLY.N), opens new tab Zepbound or Mounjaro, the injectable drugs produced smaller average weight losses than in the closely monitored clinical trials that were the basis for their approval, researchers reported on Tuesday in Obesity, opens new tab. The real-world patients took lower maintenance dosages and discontinued the drugs more often compared to participants in the clinical trials, which likely explains the lower weight losses, the researchers said. The average patient in the study had clinically severe obesity, defined as a body mass index above 39. Participants began treatment with one of the drugs between 2021 and 2023. By December 2024, 20% had discontinued the medications within 3 months of starting them, and 32% had stopped the drugs between 3 and 12 months after starting. After a year of treatment, the average weight reduction was 3.6% among those who discontinued their treatment early, compared to 6.8% for those who discontinued their treatment late. Those who did not discontinue treatment lost on average about 12% of their body weight. In the pivotal clinical trials, patients lost about 15% to 20% of their body weight. More than 80% of participants in the real-world study were on maintenance doses equal to or less than 1 milligram for semaglutide and equal to or less than 7.5 mg for tirzepatide. Semaglutide is the active ingredient in Wegovy and Ozempic, while tirzepatide is the main ingredient of Zepbound and Mounjaro. Those who did not discontinue treatment and were on higher maintenance doses of the medications lost 13.7% of their body weight with semaglutide and 18.0% with tirzepatide, close to the average weight losses seen in a recent head-to-head clinical trial comparing the drugs. About 17% of participants had pre-diabetes. In these patients, 33% of those who discontinued their treatment early achieved normal blood sugar levels, compared to 41% who discontinued their treatment late, and 67.9% who stayed on the drugs. The class of drugs to which these medicines belong were originally developed for type 2 diabetes. 'In our study, the majority of the patients with pre-diabetes experienced normal blood sugar levels when they continued their treatment,' study leader Hamlet Gasoyan of the Cleveland Clinic said in a statement. 'Type 2 diabetes is one of the most common complications of obesity, so diabetes prevention is very important. This study highlights that treatment discontinuation, especially early, negatively affects both weight and glycemic control outcomes.' The most common reasons for discontinuation of treatment included the cost of the medications and insurance coverage–related issues, side effects, and medication shortages. At-home self-testing for human papillomavirus infections could improve cervical cancer screening rates, particularly among underserved populations, researchers reported in JAMA Internal Medicine, opens new tab. In a randomized trial involving nearly 2,500 patients at a safety-net clinic, screening rates were 41% to 47% among those who received an HPV testing kit in the mail, compared with 17% among those who received only a phone-call reminder to make a clinic appointment. Self-collection kits contain swabs that allow women to collect their own vaginal sample for HPV testing, rather than have samples collected by healthcare providers during often-unpleasant pelvic exams. The swab test checks for infection with high-risk HPV types that can cause cervical cancer. Women with these high-risk types are then referred for further testing. Nearly all of the women in the study were from racial and ethnic minorities, and most were uninsured or publicly insured. Cervical cancer screening rates are well below average in such groups, but at-home testing could help improve that, the researchers said. "Too many women, especially those who are uninsured, live in rural areas or come from marginalized and underserved communities, aren't getting screened for cervical cancer,' study leader Jane Montealegre of The University of Texas MD Anderson Cancer Center said in a statement. "These results show that self-collection testing could be a solution to increasing access to screening and, in turn, reducing the burden of cervical cancer in the U.S.,' Montealegre said. In May, the Teal Wand by Teal Health became the first U.S.-approved at-home screening test for cervical cancer. (To receive the full newsletter in your inbox for free sign up here)
